Pasi, K J; Rangarajan, S; Georgiev, P; Mant, T; Creagh, M D; Lissitchkov, T; Bevan, D; Austin, S; Hay, C R; Hegemann, I; Kazmi, R; Chowdary, P; Gercheva-Kyuchukova, L; Mamonov, V; Timofeeva, M; Soh, C H; Garg, P; Vaishnaw, A; Akinc, A; Sorenson, B; Ragni, M V (2017). Targeting of antithrombin in hemophilia A or B with RNAi therapy. New England Journal of Medicine, 377(9):819-828.
Chowdary, P; Lethagen, S; Friedrich, U; Brand, B; Hay, C; Abdul Karim, F; Klamroth, R; Knoebl, P; Laffan, M; Mahlangu, J; Miesbach, W; Daalsgaard Nielsen, J; Martin-Salces, M; Angchaisuksiri, P (2015). Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. Journal of Thrombosis and Haemostasis, 13(5):743-754.
Santagostino, E; Lentz, SR; Misgav, M; Brand, B; Chowdary, P; Savic, A; Kilinc, Y; Amit, Y; Amendola, A; Solimeno, LP; Saugstrup, T; Matytsina, I (2015). Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials. Haemophilia, 21(1):34-40.